Evidence map›Paper›PMID 41729349›Full record

ArticleNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2026

Posterior reversible encephalopathy syndrome due to pituitrin for bronchiectasis with hemoptysis--a case report.

Xianru Peng, Zhongli Li, Haiting Xie, Haobo Shi, Zekui Fang

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Xianru Peng *Department of Pulmonary and Critical Care Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, 510280, China.ORCID http://orcid.org/0000-0002-6482-0388
Zhongli Li *Department of Pulmonary and Critical Care Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, 510280, China.
Haiting XieDepartment of Neurology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, 510280, China.
Haobo ShiDepartment of Radiology, Zhujiang Hospital, Southern Medical University, HaizhuGuangzhou, DistrictGuangdong, 510280, China.
Zekui FangDepartment of Pulmonary and Critical Care Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, 510280, China. 61171298@qq.com.

Funding

Science and Technology Program of Guangzhou 2024A04J4866
6 · The paper itself

Abstract

Reversible posterior encephalopathy syndrome (PRES) is a relatively rare clinical disorder characterized by reversible subcortical vasogenic edema. Pituitrin is a common medication for hemoptysis. No cases of PRES induced by pituitrin have been reported. A 52-year-old woman with bronchiectasis and hemoptysis developed hypertension, dizziness, seizures, and hemiplegia during treatment with pituitrin. Head magnetic resonance imaging showed multiple abnormal signal shadows in bilateral parieto-occipital cortex and subcortex, which was diagnosed as PRES. The patient's blood pressure returned to normal with medication, and the patient's symptoms subsequently eased and the MRI changes improved. This is the first reported case, without a history of hypertension, of the treatment of PRES secondary to bronchiectasis with hemoptysis with pituitrin. Our case report suggests that pituitrin may cause damage to the central nervous system, such as PRES. Patients who experience dizziness or other neurological symptoms during treatment with pituitrin should consider this rare complication.

Indexed as

BronchiectasisHemoptysisPosterior Leukoencephalopathy SyndromeFemaleHumansMagnetic Resonance ImagingMiddle AgedHemoptysisPituitrinPosterior reversible encephalopathy syndrome

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.